Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR19 Tregs treat murine chronic Graft-Versus-Host Disease through immune suppression in absence of measurable B-cell cytolysis.

JCI insight·2026
Same author

Sex based cardiovascular differences in adult and middle-aged hypertensive schlager mice.

Scientific reports·2025
Same author

3D vector field-guided toolpathing for 3D bioprinting.

Communications engineering·2025
Same author

Inflammasome-resistant IPSC-derived myeloid-derived suppressor cells ameliorate xenogeneic graft-versus-host disease.

Blood·2025
Same author

3D bioprinting in tissue engineering: current state-of-the-art and challenges towards system standardization and clinical translation.

Biofabrication·2025
Same author

Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202.

Blood vessels, thrombosis & hemostasis·2025

Related Experiment Video

Updated: Jun 10, 2026

Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Allogeneic natural killer cells for refractory lymphoma.

Veronika Bachanova1, Linda J Burns, David H McKenna

  • 1Blood and Marrow, Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA. bach0173@umn.edu

Cancer Immunology, Immunotherapy : CII
|August 4, 2010
PubMed
Summary

Allogeneic natural killer (NK) cell therapy shows promise for lymphoma patients, inducing objective clinical responses. However, host regulatory T cells (Tregs) may limit NK cell persistence and expansion, suggesting strategies to manage Tregs are needed.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jun 10, 2026

Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Autologous natural killer (NK) cells activated by interleukin-2 (IL-2) can induce, but not sustain, remissions in lymphoma.
  • Allogeneic NK cells are hypothesized to overcome MHC class I-mediated inhibition of NK cell killing.

Purpose of the Study:

  • To evaluate the antitumor efficacy of haploidentical donor NK cell infusion in patients with advanced B cell non-Hodgkin lymphoma (NHL).

Main Methods:

  • Six NHL patients received immunosuppression (rituximab, cyclophosphamide, fludarabine) followed by CD3-depleted NK cell-enriched products and subcutaneous IL-2.
  • Objective clinical response was assessed at 2 months.

Main Results:

  • Four out of six patients achieved an objective clinical response.
  • Early donor NK cell persistence was observed in two patients but was not detectable beyond 7 days.
  • A significant increase in host regulatory T cells (Tregs) was noted post-therapy, potentially limiting donor NK cell expansion.

Conclusions:

  • Allogeneic NK cell therapy is safe and feasible in lymphoma patients.
  • Host Tregs and insufficient immunodepletion may create an unfavorable environment for NK cell survival and expansion.
  • Future cell therapy trials should explore strategies to mitigate Treg-mediated inhibition.